Replies to post #125985 on Biotech Values

[NP1986]

Entirely different class of cancer, and entirely different thesis on how to attack the disease.

Fair enough.

At what point are you looking to sell? Based on positive news later this Fall, or do you have any hopes for the rest of CRIS' pipeline?